Prystupa Andrzej, Szpetnar Maria, Boguszewska-Czubara Anna, Grzybowski Andrzej, Sak Jarosław, Załuska Wojciech
Department of Internal Medicine, Medical University of Lublin, Lublin, Poland.
Department of Medical Chemistry, Medical University of Lublin, Lublin, Poland.
Med Sci Monit. 2015 Apr 7;21:1008-14. doi: 10.12659/MSM.892312.
Alcoholic liver disease remains one of the most common causes of chronic liver disease worldwide. The aim of this study was to assess the usefulness of metalloproteinases (MMP1 and MMP13) as diagnostic markers of alcoholic liver disease and to determine the changes in free amino acid profile in the patients with alcoholic liver cirrhosis.
Sixty patients with alcoholic liver cirrhosis treated in various hospitals of the Lublin region were randomly enrolled. The control group consisted of 10 healthy individuals without liver disease, who did not drink alcohol. Additionally, a group of alcoholics (22 persons) without liver cirrhosis was included in the study. The activity of MMP-1 and MMP-13 in blood plasma of patients and controls was measured using the sandwich enzyme immunoassay technique with commercially available quantitative ELISA test kits. Amino acids were determined by automated ion-exchange chromatography.
No significant differences were observed in the activity of MMP-1 in alcoholics with or without liver cirrhosis or in controls. Increased serum MMP-13 was found in patients with liver cirrhosis (stage A, B, C) compared to the control group. Patients with alcoholic liver cirrhosis (stage A, B, C) demonstrated reduced concentrations of glutamic acid and glutamine compared to the control group. Plasma levels of valine, isoleucine, leucine, and tryptophan were significantly lower in patients with alcoholic liver cirrhosis (stage C) than in controls.
MMP-13 can be useful to confirm the diagnosis of alcoholic liver cirrhosis, but levels of MMP-1 are not significantly increased in patients with liver cirrhosis compared to controls. The serum branched-chain amino acid (BCAA) is markedly reduced in patients with stage C alcoholic liver cirrhosis.
酒精性肝病仍然是全球慢性肝病最常见的病因之一。本研究的目的是评估金属蛋白酶(MMP1和MMP13)作为酒精性肝病诊断标志物的效用,并确定酒精性肝硬化患者游离氨基酸谱的变化。
随机纳入在卢布林地区各医院接受治疗的60例酒精性肝硬化患者。对照组由10名无肝病且不饮酒的健康个体组成。此外,一组无肝硬化的酗酒者(22人)也纳入研究。使用市售定量ELISA检测试剂盒,采用夹心酶免疫测定技术测定患者和对照组血浆中MMP-1和MMP-13的活性。通过自动离子交换色谱法测定氨基酸。
在有或无肝硬化的酗酒者以及对照组中,未观察到MMP-1活性有显著差异。与对照组相比,肝硬化患者(A、B、C期)血清MMP-13升高。与对照组相比,酒精性肝硬化患者(A、B、C期)的谷氨酸和谷氨酰胺浓度降低。酒精性肝硬化患者(C期)的血浆缬氨酸、异亮氨酸、亮氨酸和色氨酸水平显著低于对照组。
MMP-13有助于确诊酒精性肝硬化,但与对照组相比,肝硬化患者的MMP-1水平没有显著升高。C期酒精性肝硬化患者血清支链氨基酸(BCAA)明显降低。